anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Obesity affects approximately 800 million people worldwide and may contribute to various diseases, especially cardiovascular and cerebrovascular conditions. Fat distribution and content represent two related yet distinct axes determining the impact of adipose tissue on health. Unlike traditional fat measurement indices, which often overlook fat distribution, the Chinese visceral adiposity index (CVAI) is a novel metric used to assess visceral fat accumulation and associated health risks. Our objective is to evaluate its association with the risk of cardiovascular and cerebrovascular diseases.
METHODS: A nationwide longitudinal study spanning 9 years was conducted to investigate both the effects of baseline CVAI levels (classified as low and high) and dynamic changes in CVAI over time, including maintenance of low CVAI, transition from low to high, transition from high to low, and maintenance of high CVAI. Continuous scales (restricted cubic spline curves) and categorical scales (Kaplan-Meier curves and multivariable Cox regression analyses) were utilized to evaluate the relationship between CVAI and cardiovascular and cerebrovascular diseases. Furthermore, subgroup analyses were conducted to investigate potential variations.
RESULTS: Totally 1761 individuals (22.82%) experienced primary outcomes among 7717 participants. In the fully adjusted model, for each standard deviation increase in CVAI, there was a significant increase in the risk of primary outcomes [1.20 (95%CI: 1.14-1.27)], particularly pronounced in the high CVAI group [1.38 (95%CI: 1.25-1.54)] compared to low CVAI group. Regarding transition patterns, individuals who consistently maintained high CVAI demonstrated the highest risk ratio compared to those who consistently maintained low CVAI [1.51 (95%CI: 1.31-1.74)], followed by individuals transitioning from low to high CVAI [1.22 (95% CI: 1.01-1.47)]. Analysis of restricted cubic spline curves indicated a positive dose-response relationship between CVAI and risk of primary outcomes (p for non-linear = 0.596). Subgroup analyses results suggest that middle-aged individuals with high CVAI face a notably greater risk of cardiovascular and cerebrovascular diseases in contrast to elderly individuals [1.75 (95% CI: 1.53-1.99)].
CONCLUSION: This study validates a significant association between baseline levels of CVAI and its dynamic changes with the risk of cardiovascular and cerebrovascular diseases. Vigilant monitoring and effective management of CVAI significantly contribute to early prevention and risk stratification of cardiovascular and cerebrovascular diseases.
PASSIVATE is a randomized, double-blind, placebo-controlled Phase IIa trial that investigates how 12 months of treatment with AZD5718 modifies coronary plaque volume. Patients with recent STEMI or NSTEMI will receive an additional oral dose of AZD5718 (or placebo) once daily to standard clinical care for 12 months. The primary hypothesis being tested in PASSIVATE is that 12 months of treatment with AZD5718 attenuates the progression of non-calcified plaque (NCP) volume on serial computed tomography coronary angiography (CTCA) studies.

Patients who gave consent (within 30 days after their index event) will undergo a CTCA scan and start treatment (AZD5718 or Placebo). The treatment duration will be 12 months. During the treatment period, patients will come to the clinic for follow-ups. At 12 months (end treatment), the patients will undergo their 2nd CTCA scan. A follow-up visit will be performed 4 weeks after the last dose in order to ensure the safety and well-being of the patients.
The invention provides a polypeptide used for preparing bovine foot and mouth disease type O peptide vaccine. The polypeptide comprises an amino acid sequence represented by SEQ ID NO.1. The invention also provides a peptide vaccine comprising the polypeptide. The provided bovine foot and mouth disease type O synthetic peptide vaccine has good immunization effect, and does not cause problems such as fever and red swelling of traditional vaccines. Therefore, the vaccine provided by the invention is effective against current antigenic variations of foot and mouth disease, and has no biological safety problem. The vaccine is suitable for large-scale synthesis, and has good application prospect. The invention also provides preparation methods of the polypeptide and the peptide vaccine, and a pharmaceutical application thereof.
The primary objective of this project is to evaluate the functional importance of a multi function wrist compared to a single degree of freedom wrist. This will be accomplished through in laboratory testing and an 8-week home trial. The first aim will involve in-laboratory functional performance testing with a 1-DOF or a 2-DOF wrist and a one degree of freedom hand.

Changes in performance will be assessed with multiple outcome measures that include both quantitative and qualitative testing of prosthesis control and functional performance. The second aim will determine how a 2-DOF wrist impacts control and home use of a one degree of freedom hand. Subjects will compete an 8 week home based trial. Participants will be instructed to complete a written home log of activities and electronic logging usage data will also be collected for each experimental condition. The investigators hypothesize that adding a wrist flexion/extension module to a wrist rotation module and a single-DOF terminal device will provide significant improvements in function for transradial amputees.
<P>PROBLEM TO BE SOLVED: To obtain a chitosan sponge being useable for applications such as cosmetics, medical materials, and industrial materials, excellent in water-absorbing characteristics, especially water-absorbing rate, water-absorbing magnification and having high flexibility.  <P>SOLUTION: The method for producing the chitosan sponge comprises adding polyethylene glycol or polypropylene glycol having 1,500-8,000 molecular weight when producing the porous chitosan sponge from a chitosan solution. Thereby, water absorbing characteristics are remarkably improved. The chitosan sponge is used for application such as cosmetics, e.g. pack materials for the faces and the skins and medical materials, e.g. wound-covering materials.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND AND OBJECTIVES: The resorption of flap's volume can be frequently observed in the transplantation of microvascular free flaps, which could significantly affect postoperative function. Therefore, it's essential to comprehend the postoperative flap volume and the mechanisms behind before making clinical decisions.
METHODS: Literature search was conducted from database on PubMed, EMBASE, Cochrane Library, Chinese database and Google Scholar. A random effects model meta-analyses and descriptive systematic review were performed.
RESULTS: The search identified 420 articles, of which 9 studies included in meta-analysis and 14 studies included in descriptive systematic review. Postoperative flap volume maintenance rate is used to represent the volume change. The pooled mean postoperative flap volume maintenance rate was 62.82 % for soft tissue flap (95 %CI: 58.83 to 66.82, p = 0.076, I2=56.3 %) and 85.96 % for bone flap (95 %CI: 84.19 to 87.73, p = 0.274, I2=20.4 %). Weight loss, muscle atrophy, and decreased serum albumin levels are risk factors for postoperative volume reduction of soft tissue flaps. The bone resorption rate of bone flaps in women is higher than that in men.
CONCLUSION: When designing microvascular free flaps for oral and maxillofacial surgery, soft tissue flaps should consider an anticipated postoperative shrinkage of 37 %, while bone flaps should consider an anticipated postoperative shrinkage of 14 %.
The present invention relates to an antimicrobial composition comprising an extract of plants of Suaeda spp. as an active ingredient. More particularly, the present invention relates to an antimicrobial composition comprising an extract of plants of Suaeda spp. selected from the group consisting of Suaeda japonica, Suaeda glauca, Suaeda australis and Suaeda malacosperma, as an active ingredient. The extract of plants of Suaeda spp. as an active ingredient of the antimicrobial composition according to the present invention shows a strong antimicrobial effect as demonstrated by the examples described in the specification, and particularly has excellent heat stability and causes no degradation of antimicrobial activity even under an acidic condition of pH 2 and in the plasma. Thus, the extract according to the present invention can be processed into various forms, such as extract solution, powder, pills or tablets, and is useful for applications, including pharmaceutical compositions, health-aid foods, livestock feed additives, industrial disinfectants, industrial preservatives, antimicrobial living goods or pharmaceutical additives.
Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
FIELD: in medicine as histamine receptors in treating gastrointestinal disorders. SUBSTANCE: salts formed by ranitidine and a bismuth-carboxylic acid complex or a solvate of said salts. Reagent 1: ranitidine. Reagent 2: a bismuth-carboxylic acid complex, the acid being selected from tartaric or citric acid. Reaction conditions: the process is carried out in an aqueous solution at a temperature not higher than 100 C and the resulting salt is isolated from the solution. The salt shows antisecretory activity typical of ranitidine in combination with a bactericidal activity to Campylobocter, Pylori and also has cytoprotecting activity. EFFECT: improved properties of the salt. 3 cl
The study was designed as a cross-sectional analysis of gender differences in dietary patterns and physical activity, utilizing Principal Component Analysis (PCA) to identify distinct behavioral groups. A total of 2,509 participants were recruited from a metabolic health center in Rome, Italy, between May 2023 and June 2024. The study collected detailed data on eating habits, physical activity, and body composition through questionnaires and bioimpedance analysis. Five distinct behavioral groups were identified through PCA, with significant differences in dietary patterns and physical activity levels between men and women. Men were found to consume more meat and participate in strength training, while women favored vegetable-rich diets and had more structured eating routines. These differences also translated into body composition, with men having more lean mass and women more fat mass.

The study highlights the importance of gender-specific interventions in nutrition and physical activity to improve metabolic health outcomes. The results suggest that men could benefit from increased vegetable consumption, while women could benefit from engaging in more physical activity, particularly strength training. Future research should explore these patterns longitudinally to better understand how these behaviors evolve over time and to develop more tailored interventions.
The aim of this study was to compare the effects of expiratory muscle training (EMT) and incentive spirometry (IS) in addition to conventional pulmonary rehabilitation after colorectal surgery. Twenty-four individuals (13 male) undergoing colorectal surgery were included. They were randomly divided into two groups. In addition to conventional chest physiotherapy, group 1 was performed EMT (n=12), group 2 was performed deep breathing exercises with incentive spirometry (IS) in postoperative period. Respiratory muscle strength, functional capacity, levels of movement and independence, and postoperative pulmonary complications (PPC) were evaluated. Length of stay in hospital (LOS) was recorded
At time of consent and within 14 days of surgery, patients complete a pre-operative geriatric assessment that evaluates functional status, comorbid medical conditions, psychological state, social support, and nutritional status. Post-operative complications are also collected for 6 weeks after surgery or until the date patients initiate or restart chemotherapy whichever is first.
The invention relates to a controlled-release antibiotic hydrogel and a preparation method and application thereof. The invention provides an aminoglycoside antibiotic-based controllable-release antibiotic hydrogel which is formed by cross-linking oxidized polysaccharide macromolecules and aminoglycoside antibiotics through acid-sensitive Schiff base bonds, wherein the Schiff base bonds are broken under an acidic environment generated by bacterial infection, so that gel degradation is caused, and the antibiotics can be released as required. The invention also provides the antibacterial application of the oxidized polysaccharide-aminoglycoside antibiotic hydrogel in vitro and in vivo. The preparation method is simple, the cost is low, the prepared controlled-release antibiotic hydrogel can control the strength of the gel, the appearance of the gel, the degradation of the gel, the release rate of the drug and the like according to the antibiotic content, and has very broad-spectrum efficient antibacterial performance, and the antibacterial effect is superior to various commercial antibacterial gels on the market. The hydrogel is expected to be made into cream, implant, coating on medical apparatus, etc. for resisting infection of gram-negative bacteria, gram-positive bacteria, etc.
Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management. The study features only one group. Participants will receive the intervention described. There is no control group.
###  Metyrosine Crystalluria: Crystalluria and urolithiasis have been found in dogs treated with Metyrosine at doses similar to those used in humans, and crystalluria has also been observed in a few patients. To minimize the risk of crystalluria, patients should be urged to maintain water intake sufficient to achieve a daily urine volume of 2000 mL or more, particularly when doses greater than 2 g per day are given. Routine examination of the urine should be carried out. Metyrosine will crystallize as needles or rods. If metyrosine crystalluria occurs, fluid intake should be increased further. If crystalluria persists, the dosage should be reduced or the drug discontinued.

###  Relatively Little Data Regarding Long-Term Use: The total human experience with the drug is quite limited and few patients have been studied long term. 

### Chronic animal studies have not been carried out. Therefore, suitable laboratory tests should be carried out periodically in patients requiring prolonged use of Metyrosine and caution should be observed in patients with impaired hepatic or renal function.
The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
The aging process in the elderly results in heightened skin fragility associated with various disorders, including pressure ulcers (PUs). Despite the high incidence of PUs in the elderly population, there is a limited body of research specifically examining the impact of aging on the development of pressure ulcers. Therefore, investigating age-related physiological abnormalities is essential to elucidate the pathogenesis of PUs. Ischemia-reperfusion (I/R) injury and the subsequent oxidative stress caused by reactive oxygen species (ROS) play essential roles in the early stage of PUs. In this study, we used a mouse model of proteasomal dysfunction with an age-related phenotype to examine the role of proteasome activity in cutaneous I/R injury in vivo. Decreased proteasome function did not affect the expression of inflammatory cytokines and adhesion molecules in the I/R area in transgenic mice; however, proteasome inhibition increased oxidative stress that was not attenuated by activation of the oxidative stress response mediated by NF-E2-related factor 2 (Nrf2). In dermal fibroblasts (FCs) subjected to hypoxia-reoxygenation (H/R), proteasome inhibition induced oxidative stress and ROS production, and Nrf2 activation did not adequately upregulate antioxidant enzyme expression, possibly leading to antioxidant/oxidant imbalance. The free radical scavenger edaravone had protective effects against I/R injury in vivo and decreased oxidative stress in FCs treated with a proteasome inhibitor and subjected to H/R in vitro. The results suggest that the age-related decline in proteasome activity promotes cutaneous I/R injury-induced oxidative stress, and free radical scavengers may exert protective effects by preventing oxidative stress in the early stage of PUs.
Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
Enrolled patients will receive two standard forms of inhaled medications as ordered by the physician. Patients will be randomized into two paths of the cross over study. There will be no blinding involved in this randomization. Path A will have medications delivered trans-nasally in line via the vibrating mesh nebulizer (VMN) with the high flow nasal cannula followed by standard jet nebulization (SJN) with face mask at the next time of medication dosing 3-6 hours later.
Bronchial epithelium exposed to cigarette smoke undergoes a series of histological changes that may ultimately lead to invasive cancer. In rats exposed to cigarette smoke inhaled corticosteroids reduce the number of lung tumors. The purpose of this study is to assess the efficacy of fluticasone on premalignant lesions in volunteers with a smoking history of \>10 pack-years and patients cured of head and neck cancer or lung cancer. Participants are screened for premalignant lesions by bronchoscopy and if these are present randomised to receive a powder inhalation device containing either fluticasone 500 μg or a placebo. After 6 months, biopsies are taken from the same locations. Efficacy of treatment is assessed by reversal of metaplasia/dysplasia; secondary end-points are reversal of increased p53 immunoreactivity and hTERT expression.
The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
Premature Closure of Fetal Ductus Arteriosus:

Avoid use of NSAIDs, including Orphengesic Forte Tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including Orphengesic Forte Tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment:

Use of NSAIDs, including Orphengesic Forte Tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit Orphengesic Forte Tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if Orphengesic Forte Tablets treatment extends beyond 48 hours. Discontinue Orphengesic Forte Tablets if oligohydramnios occurs and follow up according to clinical practice [ see PRECAUTIONS; Pregnancy] .
Patients between the ages of 18 and 100 who will apply to our hospital due to rib fractures between April 2024 and April 2025 will be evaluated. Patients who meet the inclusion criteria will be included in the study. Patients will be divided into two groups using randomization blocks. Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen. In the other group of patients, in addition to conservative treatment, triflow breathing exercise will be applied for 8 hours a day. Respiratory function test pain scores and pulmonary complications of patients in the two groups will be compared statistically.
A method and medicant for the inhibition of activation of the nuclear transcription NF-B comprising administering an effective amount of a compound of formula (I) where R = ethylene, R~= C4 to C14 straight chain or branched alkyl, x is greater than 1, and y = 8 to 18, is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably, the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein said medicant includes an anti-inflammatory steroid. In addition, a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF, is provided.
PURPOSE:The titled composition, obtained by stably blending a magnesium compound-containing water-soluble high polymer as a base with minocycline which is a tetracycline based antibiotic substance and forming the resultant blend into a film, etc., directly applicable to periodontal affected parts and sustainedly exhibiting effect without side effect. CONSTITUTION:A filmy or sheetlike composition obtained by blending a water- soluble high polymer with minocycline or a pharmaceutically acceptable salt thereof and magnesium compound. The minocycline blended in the composition may be either one of free form and a pharmaceutically acceptable salt, e.g. hydrochloride, sulfate, etc., in an amount within the range of 0.1-10.0wt% based on the total composition. Magnesium chloride is particularly preferred for the magnesium compound and the amount thereof blended is within the range of up to 20wt% based on the total of the composition and in an amount of 0.1-10 times based of the minocycline. Hydroxypropyl cellulose is particularly preferred for the water-soluble high polymer.